

* NOTICES *

JPO and INPIT are not responsible for any damages caused by the use of this translation.

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.**** shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

MEANS

[Means for Solving the Problem]This invention is an osteoporosis treating agent containing EPA-E as an active principle.

[0009]When this invention person inquired wholeheartedly about a safe remedy to osteoporosis, he found out that EPA-E is very useful to prevention and an improvement of advance of a clinical top and osteoporosis, and that it was useful in especially an I-beam. In this invention, prevention of the disease concerned is also included with a therapy.

[0010]Hereafter, this invention is explained in detail.

[0011]EPA-E in this invention refers to all the - ****- 5, 8, 11, and 14 and 17-ethyl icosapentate (ethyl all-cis-5, 8, 11 and 14, 17-icosapentaenoate), It can obtain by carrying out fish oil besides a commercial item by the ability to carry out refining and esterification treatment by a publicly known method.

[0012]in an active principle of a treating agent of this invention, EPA-E can use the pure article -- of course -- a fatty acid content -- 85 % of the weight or more can also use a thing of EPA-E preferably 50% of the weight or more.

[0013]A class of a suitable carrier or a medium which a treating agent of this invention prescribes an active principle for the patient with a compound independent, or is generally used, An excipient, a binding material, lubricant, colorant, a flavor agent, and if needed For example, sterilized water and vegetable oil, an innocence organic solvent or an innocence solubilizing agent (for example, glycerin, propylene glycol), an emulsifier, a suspending agent (for example, Tween 80, a gum arabic solution), etc. -- suitably -- selection ***** -- it can prepare to suitable pharmaceutical preparation for medicines.

[0014]As for the above-mentioned pharmaceutical preparation, since EPA-E is highly unsaturated, it is desirable to make quinone and alpha-tocopherol which approve as an anti-oxidant, for example, butyrate-ized hydroxytoluene, butyrate-ized hydroxyanisole, propyl gallate, and medicine and in which it deals further contain.